- Australian agricultural microbial products company Terragen Holdings Ltd 
launches a $20 million initial public offer (IPO) of shares, comprising 80 
million shares at 25 cents per share 

- Terragen has developed and commercialised a range of biological products that 
use live microbes to address soil health and the productivity of farm 
production animals 

- Terragen believes that its suite of biological products can provide farms 
with a foundation to be more sustainable

Australian agricultural biotechnology company Terragen Holdings Ltd ("Terragen" 
or "the Company") has launched a $20 million initial public offer (IPO) of 
shares ahead of an anticipated listing on the Australian Securities Exchange 
(ASX) in early December.

Terragen has developed and commercialised a range of biological products that 
use live microbes to address soil health and help boost the growth, quality and 
resilience of farm production animals. The Company aims to reduce the reliance 
of farmers on chemical-based fertilisers, pesticides and antibiotics.

Terragen already has two products on the market in Australia and New Zealand: 
the soil conditioner 'Great Land' and microbial feed supplement 'Mylo(R)'. 
Terragen is also developing veterinary medicines: Lactolin, a teat conditioner 
to maintain and improve the udders of lactating production animals; and Halo, 
an anti-inflammatory product to assist dairy cattle with mastitis and companion 
animals such as dogs with mobility impairments.

Terragen is offering 80 million fully paid ordinary shares at an Offer Price of 
$0.25 per ordinary share to raise $20 million.

Funds raised under the Offer will be used to further commercialise Great Land 
and Mylo(R) in Australia and New Zealand, to further develop and subsequently 
market Mylo(R), Lactolin and Halo in the United States and Europe, and to 
continue to improve the production efficiency and formulation of Terragen 
products.

"Terragen provides an important contribution to reduce farmer's dependency on 
synthetic chemicals for production inputs," said Terragen Chairman, Sam 
Brougham. "We believe that our biological products can help generate better 
outcomes for farmers with their crops and livestock and provide better 
environmental outcomes that will be more acceptable to consumers."

Terragen Managing Director and Chief Executive Officer, Justus Homburg, said 
Terragen believes that its suite of biological products can provide farms with 
a means to be more sustainable.

"Terragen is well placed to help unlock a new future for farming," Mr Homburg 
said. "We produce biological products that provide a foundation for driving 
agricultural sustainability on farms using organic, chemical-free or 
conventional farming practices."

Terragen's growth strategy focuses on increasing the scale and distribution 
networks for Great Land and Mylo® in Australia and New Zealand; rolling out 
Terragen products in key dairy markets in Australia, New Zealand and the United 
States; and assessing market potential in selected countries of the European 
Union.

Terragen has identified the dairy sector as a key platform for growth due to 
the large addressable market.

The Offer comprises a fully underwritten Broker Firm Offer, Institutional Offer 
and Chairman's List Offer. There is no general public offer of shares under the 
Offer.

The Offer opens on 5 November 2019 and closes on 21 November 2019.

The Joint Lead Managers are Bell Potter Securities Ltd and Evans Dixon 
Corporate Advisory Pty Ltd.

Potential investors can read the Terragen IPO Prospectus on the Company's 
website here (https://events.miraqle.com/Terragen-IPO/Country-Validation/).

This news release does not constitute an offer to sell or a solicitation of an 
offer to buy any shares in the Company.

Details of the IPO 

The Company will offer 80,000,000 shares at an issue price of $0.25 per share, 
to raise $20 million before expenses. 

To participate in the IPO 

The Offer is being made under a Prospectus lodged with ASIC on 18 October 2019 
("Prospectus") and is available at www.terragen.com.au.  No general public 
offer of the shares will be made under the Offer.  Offers will be made in, or 
accompanied by, a copy of the Prospectus. A person should consider the 
Prospectus in deciding whether to acquire shares. Anyone who wants to acquire 
shares will need to complete the application form that will be in or will 
accompany the Prospectus. 

Underwriting 

The Offer has been fully underwritten by the Joint Lead Managers and 
Underwriters to the Offer, Bell Potter Securities Limited and Evans Dixon 
Corporate Advisory Pty Ltd. 

Proposed Key Dates* 

Opening Date of Offer                                    5 November 2019 
 
Closing Date of Offer                                    21 November 2019 
 
Allotment of New Shares -- under the Institutional       5 December 2019 
Offer, Chairman's List Offer and Broker Firm Offer 
 
Expected dispatch of Shareholder holding statements      6 December 2019 
 
Shares expected to commence trading on ASX on a normal   11 December 2019
settlement basis  
  
*subject to change 

SOURCE Terragen Holdings Ltd